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Abstract
Introduction: Periductal stromal sarcoma is an extremely rare malignant fibroepithelial tumor of the breast which is
characterized by its biphasic histology with benign ductal elements and a sarcomatous stroma made of spindle cells
and lacking phyllodes architecture. Its therapeutic management is based on wide surgery with free margins.
Adjuvant therapies are not needed. Periductal stromal sarcoma may evolve into a phyllodes tumor with time, as well
as a specific soft-tissue sarcoma. To the best of our knowledge, this tumor has never been described in a child.
Case presentation: A 14-year-old Arabic boy was presented to our hospital one year ago with a nodule of the
right breast that was gradually increasing in size without signs of inflammation. The histological examination after
lumpectomy revealed a periductal stromal sarcoma with free surgical margins. No adjuvant treatment was given.
At 50 months of close follow-up, no recurrence was observed.
Conclusion: Periductal stromal sarcoma in a child is a very rare disease which has the same indolent behavior as it
does in adults. Therefore, close follow-up is required.
Introduction
Periductal stromal sarcoma (PSS) is an extremely rare
neoplasm arising in the connective tissue of the breast,
especially from the periductal stroma [1]. In this care
report, we describe the first such case in a child
reported in the literature. Diagnostic problems due to
the lack of phyllodes tumors cause diagnostic problems,
because PSS is a distinct, low-grade breast sarcoma with
no clinical or radiological specificity. Regarding its ther-
apeutic management, surgery with safe margins is the
ideal treatment, and the efficacy of adjuvant treatment
(for example, chemotherapy or radiotherapy) remains to
be demonstrated [2,3].
Case presentation
We report the clinical case of a 14-year-old Arabic boy
with no history of disease who was presented to our
hospital one year ago with a nodule of the right breast
that was gradually increasing in size. Upon clinical
examination, we found, in the upper outer quadrant of
the right breast, a small mass measuring approximately
2cm in size, round in shape, with no signs of inflamma-
tion and not associated with axillary lymph nodes. He
underwent a lumpectomy. Grossly, the tumor was well
circumscribed, nodular, andw e l ld e l i n e a t e da n dm e a -
sured 1.5 cm × 1 cm. Microscopic examination revealed
no leafy architecture, but we found a biphasic prolifera-
tion composed of epithelial and mesenchymal compo-
nents. The epithelial component corresponded to ducts
with borders, sometimes double and sometimes with
mild to moderate hyperplasia without atypia. These duc-
tal structures were often dilated and surrounded by a
spindle-cell mesenchymal tumor which showed moder-
ate cellular density and mitotic activity of about two to
three mitoses/10 high-power fields (Figure 1, Figure 2
and Figure 3). These mesenchymal cells showed moder-
ately hyperchromatic nuclei of variable sizes, sometimes
with distinct nucleoli. The closest distance between the
tumor and resection margins ranged from 2mm to
13mm. Immunohistochemistry showed the tumor cells
to be CD34-positive (Figure 4) and S-100-, ER- and PR-
negative. The lesion was histologically compatible with
low-grade PSS. The resection margins were negative
(range, 2mm to 13mm). No adjuvant treatment was
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did not show any symptoms or signs of local or distant
recurrence.
Discussion
Previously classified with cystosarcoma with adipose
metaplasia [2,4-7], PSS was recently recognized as a
separate entity and was given its own place in the
World Health Organization classification system at the
consensus conference in Lyon in 2002 [1].
PSS occurs in pre and post menopausal women with a
median of age of 55.3 years [2], and before the present
case report it had never been described in a child. The
symptoms most commonly found are similar to other
benign and malignant breast tumors and have no radi-
ological specificity [2].
In the presence of a breast lump in boys, clinicians
must eliminate gynecomastia, which is a soft swelling or
enlargement of the breast tissue under the nipple caused
by the hormonal changes that occur during adolescence.
Histologically, PSS is a biphasic breast tumor with
benign ductal elements and a sarcomatous stroma lack-
ing phyllodes architecture. This tumor is characterized
by a hypercellular proliferation of spindle cells forming
cuffs around well-preserved ductal units with infiltration
of the fat and surrounding tissue. Adjacent cuffs may
coalesce to form large nodules and extend into lobules
surrounding open tubules and ducts. This is in contrast
to mammary stromal sarcomas, which displace normal
mammary tissue, entrapping ducts and lobules peripher-
ally [3].
The histological features of PSS were defined by the
Armed Forces Institute of Pathology (AFIP) [2] as
Figure 1 Stromal periductal proliferation arranged within fat
tissue (hematoxylin and eosin stain; original magnification, × 50).
Figure 2 Regular epithelial structures surrounded by a mildly
cellular stroma (hematoxylin and eosin stain; original
magnification, × 100).
Figure 3 Periductal stromal sarcoma. Epithelial structure
surrounded by a stroma with moderate atypical cells showing
mitosis.
Figure 4 Periductal stromal sarcoma cells are CD34-positive.
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eration of variable cellularity and atypia around open
tubules and ducts devoid of a phyllodes pattern; (2) one
o r ,m o r eo f t e n ,m u l t i p l en o d u l e ss e p a r a t e db ya d i p o s e
tissue; (3) stromal mitotic activity of ≥3/10 high-power
fields; and (4) infiltration into surrounding mammary
fibroadipose tissue.
Immunohistochemistry reveals the tumor cells to be
positive for a smooth muscle actin CD34. They are
often CD117 and do not express S-100 protein, estro-
gen, or progesterone receptors [2,8,9]. The histological
grading depends on atypia and mitotic activity, so it
ranges from being low-grade to high-grade PSS [2].
Because the number of reported cases in the literature
is so small, the optimal means of managing PSS has yet
to be established. Currently, resection with adequate
margins is generally considered sufficient, and axillary
lymphadenectomy is not needed. With regard to adju-
vant therapy, the scant literature does not show any
benefit of radiotherapy or chemotherapy.
PSS is a tumor of intermediate behavior; it may evolve
into a phyllode tumor as well as a specific soft-tissue
sarcoma. Also, PSS may occasionally exhibit intraepithe-
lial changes ranging from ordinary hyperplasia to intra-
ductal carcinoma [2,3]. Therefore, close follow-up is
needed. Our patient is currently recurrence-free 50
months after treatment.
Conclusion
In summary, because there is so little experience with
PSS, its management remains controversial. Its histologi-
cal diagnosis is based on the criteria established by the
AFIP. Surgery with safe margins is the cornerstone of
treatment. The prognosis of patients with PSS is
unclear; thus, more cases of this unusual morphologic
variant and longer follow-up of existing and future
patients are needed to determine the optimal manage-
ment and the clinical behavior of this neoplasm.
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